Scholarlink

Background <p>Semaglutide, a GLP-1 receptor agonist widely prescribed for type 2 diabetes and obesity, has recently raised concerns about its ocular safety. This study aimed to investigate the association between semaglutide use and vision impairment using data from the FDA Adverse Event Reporting System (FAERS).</p> Methods <p>We conducted an analysis of FAERS data, comparing reports of vision impairment associated with semaglutide to those associated with other antidiabetic and weight loss medications. The main outcome measure was the reporting odds ratio (rOR) for vision impairment linked to semaglutide use compared to other medications.</p> Results <p>Semaglutide showed significantly higher reporting of vision impairment compared to other GLP-1 receptor agonists (rOR 1.95, 95% CI 1.75–2.17, <i>p</i> &lt; 0.0001), DPP-4 inhibitors (rOR 2.46, 95% CI 2.12–2.86, <i>p</i> &lt; 0.0001), SGLT2 inhibitors (rOR 3.89, 95% CI 3.35–4.51, <i>p</i> &lt; 0.0001), and metformin (rOR 2.23, 95% CI 1.90–2.62, <i>p</i> &lt; 0.0001). Similar findings were observed when compared to phentermine (rOR 1.57, 95% CI 1.07–2.31, <i>p</i> = 0.026) and orlistat (rOR 3.77, 95% CI 2.96–4.81, <i>p</i> &lt; 0.0001). Topiramate was the sole exception, showing higher vision impairment reporting than semaglutide (rOR 0.30, 95% CI 0.20–0.45, <i>p</i> &lt; 0.0001).</p> Conclusions <p>These findings suggest a potentially elevated risk of vision impairment with semaglutide use compared to other diabetes and weight loss medications, warranting further investigation and vigilant post-marketing surveillance. Future studies should assess the clinical impact of this potential increased risk on an absolute scale to better inform treatment decisions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月7日

查看全文
  • Marine Massy,
  • Stefanie Marti,
  • Helly Hammer,
  • Robert Hoepner

摘要

Background

Semaglutide, a GLP-1 receptor agonist widely prescribed for type 2 diabetes and obesity, has recently raised concerns about its ocular safety. This study aimed to investigate the association between semaglutide use and vision impairment using data from the FDA Adverse Event Reporting System (FAERS).

Methods

We conducted an analysis of FAERS data, comparing reports of vision impairment associated with semaglutide to those associated with other antidiabetic and weight loss medications. The main outcome measure was the reporting odds ratio (rOR) for vision impairment linked to semaglutide use compared to other medications.

Results

Semaglutide showed significantly higher reporting of vision impairment compared to other GLP-1 receptor agonists (rOR 1.95, 95% CI 1.75–2.17, p < 0.0001), DPP-4 inhibitors (rOR 2.46, 95% CI 2.12–2.86, p < 0.0001), SGLT2 inhibitors (rOR 3.89, 95% CI 3.35–4.51, p < 0.0001), and metformin (rOR 2.23, 95% CI 1.90–2.62, p < 0.0001). Similar findings were observed when compared to phentermine (rOR 1.57, 95% CI 1.07–2.31, p = 0.026) and orlistat (rOR 3.77, 95% CI 2.96–4.81, p < 0.0001). Topiramate was the sole exception, showing higher vision impairment reporting than semaglutide (rOR 0.30, 95% CI 0.20–0.45, p < 0.0001).

Conclusions

These findings suggest a potentially elevated risk of vision impairment with semaglutide use compared to other diabetes and weight loss medications, warranting further investigation and vigilant post-marketing surveillance. Future studies should assess the clinical impact of this potential increased risk on an absolute scale to better inform treatment decisions.